Contact
Therapeutic Modalities | Q&As & Interviews

Targeting Solid Tumours With TCR Guided NK Cells

05 May 2022
Video Interview | Namir Hassan, CEO at Zelluna Immunotherapy
https://www.youtube.com/watch?v=7n_7aOjsa50

Speaker Biographies

Namir Hassan serves as CEO of Zelluna Immunotherapy. He has over 15 years of biotech and pharma industry experience spanning from target validation through to early phase clinical trials and has mostly focussed on Oncology and the development of immunotherapies. Prior to joining Zelluna, Namir was VP at Immunocore responsible for building and overseeing research biology and translational science for the Oncology pipeline then building a unit focussed on deployment of the platform in infectious diseases.
Previously, Namir had a leadership role in the discovery research organization within GSK and has worked at the Ludwig Institute for Cancer Research. Namir received a DPhil from the University of Oxford in T-cell Biology.

Related Resources

Positive Results from iNKT Cell Therapy Clinical Trial for COVID-19 ARDS

The small exploratory trial shows signs that iNKT cells can improve the survival rate of respiratory distress from COVID-19.
Read More

How to Improve Therapeutic Efficacy: Safety Considerations in Oncolytic Virotherapy

Oncolytic virotherapy targets cancer cells with viruses, promising personalized treatment with minimal side effects. Safety measures include minimizing off-target effects and systemic spread. Combining with immunotherapy enhances efficacy, revolutionizing cancer treatment.
Read More

Related Online Activities

Join the conversation with our upcoming Monthly Science Exchanges and Webinars:
08/04/24
Harnessing The Immune System With NK Cell Engagers
03/06/24
Target Identification for ADCs